Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real‐world study for patients with hormone receptor‐positive and HER2‐negative advanced breast cancer

Fulvestrant 500 mg is standard of care for endocrine therapy‐naive or pretreated women with hormone receptor‐positive (HR+) metastatic breast cancer (MBC). This study was conducted to explore the potential factors and duration of last endocrine therapy as predictors for the efficacy of fulvestrant 5...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Med
Autores principales: Zhao, Yannan, Li, Yi, Gong, Chengcheng, Xie, Yizhao, Zhang, Jian, Wang, Leiping, Cao, Jun, Tao, Zhonghua, Wang, Biyun, Hu, Xichun
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7724295/
https://ncbi.nlm.nih.gov/pubmed/33022852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3491
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares